Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
The 15 Most Powerful Forerunners in Business - 2A mom's viral post is raising the question: Do kids need snacks? Dietitians have answers.
- 3Ethiopian earthquakes and volcanic eruptions: earth scientist explains the link
- 4US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships
- 5Undeniably popular Historical centers: Where Craftsmanship and History Meet
- Ski Resorts Universally: A Colder time of year Wonderland Guide
- Metropolitan Greatness: The 6 Urban areas for Quality Living in 2024
- 6 Savvy Locks for Lofts
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Investigating Remarkable Espresso Flavors: Upgrade Your Day to day Blend
- Israeli strike on Gaza City vehicle kills at least four, report says
- IDF strikes Hamas terror base in Lebanon, Health Ministry says 11 killed
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
- US FDA approves Kura-Kyowa's blood cancer therapy
